Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation
Open Access
- 16 July 2020
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 8 (1), e001319
- https://doi.org/10.1136/bmjdrc-2020-001319
Abstract
Introduction A growing body of evidence suggests that specific, naturally occurring gut bacteria are under-represented in the intestinal tracts of subjects with type 2 diabetes (T2D) and that their functions, like gut barrier stability and butyrate production, are important to glucose and insulin homeostasis. The objective of this study was to test the hypothesis that enteral exposure to microbes with these proposed functions can safely improve clinical measures of glycemic control and thereby play a role in the overall dietary management of diabetes. Research design and methods We evaluated whether a probiotic comprised of these anaerobic bacteria would enhance dietary management by (1) manufacturing two novel probiotic formulations containing three (WBF-010) or five (WBF-011) distinct strains in a Current Good Manufacturing Practice (cGMP) facility, (2) establishing consistent live-cell concentrations, (3) confirming safety at target concentrations dispensed in both animal and human studies and (4) conducting a 12-week parallel, double-blind, placebo-controlled, proof-of-concept study in which subjects previously diagnosed with T2D (n=76) were randomly assigned to a two times a day regimen of placebo, WBF-010 or WBF-011. Results No safety or tolerability issues were observed. Compared with the placebo group, subjects administered WBF-011 (which contains inulin, Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Bifidobacterium infantis and Anaerobutyricum hallii) significantly improved in the primary outcome, glucose total area under the curve (AUC): −36.1 mg/dL/180 min, p=0.0500 and also improved in secondary outcomes, glycated hemoglobin (A1c): −0.6, glucose incremental-AUC: −28.6 mg/dL/180 min. Conclusions To our knowledge, this is the first randomized controlled trial to administer four of the five strains to human subjects with T2D. This proof-of-concept study (clinical trial number NCT03893422) shows that the intervention was safe and well tolerated and that supplementation with WBF-011 improves postprandial glucose control. The limited sample size and intersubject variability justifies future studies designed to confirm and expand on these observations.Keywords
This publication has 45 references indexed in Scilit:
- Diet rapidly and reproducibly alters the human gut microbiomeNature, 2013
- An increase in theAkkermansiaspp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese miceGut, 2013
- Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesityProceedings of the National Academy of Sciences of the United States of America, 2013
- Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic SyndromeGastroenterology, 2012
- Microbes inside—from diversity to function: the case of AkkermansiaThe ISME Journal, 2012
- Genetic predisposition, Western dietary pattern, and the risk of type 2 diabetes in menThe American Journal of Clinical Nutrition, 2009
- Mucosal Glycan Foraging Enhances Fitness and Transmission of a Saccharolytic Human Gut Bacterial SymbiontCell Host & Microbe, 2008
- Two Routes of Metabolic Cross-Feeding between Bifidobacterium adolescentis and Butyrate-Producing Anaerobes from the Human GutApplied and Environmental Microbiology, 2006
- Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacteriumInternational Journal of Systematic and Evolutionary Microbiology, 2004
- Dietary-fiber Hypothesis of the Etiology of Diabetes MellitusDiabetes, 1975